help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garrel, D. R.
Right arrow Articles by Tourniaire, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garrel, D. R.
Right arrow Articles by Tourniaire, J.

Journal of Clinical Endocrinology & Metabolism, Vol 62, 1052-1055, Copyright © 1986 by Endocrine Society

ARTICLES

Serum bone Gla protein: a marker of bone turnover in hyperthyroidism

DR Garrel, PD Delmas, L Malaval and J Tourniaire

Serum bone Gla protein (BGP) concentrations were measured in 24 hyperthyroid patients before and after treatment. Before treatment, the mean concentration was higher [11.8 +/- 3.4 ( +/- SD) ng/ml] in the patient group than in a group of 12 age-matched normal subjects (6.1 +/- 1.7 ng/ml; P less than 0.001); 16 of the 24 patients had a value above the normal range. Serum BGP concentrations in the patients correlated significantly with serum T3 (r = 0.65; P less than 0.001) and T4 concentrations (r = 0.56; P less than 0.01). Other biochemical markers of bone metabolism (serum alkaline phosphatase, serum and urinary calcium, and urinary hydroxyproline) did not correlate with circulating thyroid hormone levels. Serum BGP also was measured after the patients had become euthyroid; 23 measurements were made on 16 patients at various times after the start of treatment. All values were normal after 16 weeks; before this period, most of the values were still above the normal range despite normal plasma thyroid hormone concentrations in all patients. These results suggest that BGP is a sensitive marker of bone metabolism alterations during hyperthyroidism.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
H. Pantazi and P. D. Papapetrou
Changes in Parameters of Bone and Mineral Metabolism during Therapy for Hyperthyroidism
J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1099 - 1106.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Siddiqi, J. M. Burrin, K. Noonan, I. James, D. F. Wood, C. P. Price, and J. P. Monson
A Longitudinal Study of Markers of Bone Turnover in Graves' Disease and Their Value in Predicting Bone Mineral Density
J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 753 - 759.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Cioffi, A. M. Molinari, P. Gazzerro, B. Di Finizio, M. Fratta, A. Deufemia, and G. A. Puca
Serum Osteocalcin in 1634 Healthy Children
Clin. Chem., March 1, 1997; 43(3): 543 - 545.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society